February 19, 2019

Dr. Wes Van Voorhis, Director of CERID, recently reflected on some exciting developments within CERID.

January 29, 2019

CERID Researchers published in The Journal of Infectious Diseases: "Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis."

December 18, 2018

Researchers explore the latest advances in Cryptosporidium research at Tufts University.

October 31, 2018

Dr. Wes Van Voorhis is conducting a Phase 2A, clinical trial on the safety, tolerability, pharmacokinetics and efficacy of clofazimine in Cryptosporidiosis.